drugset
drugset / Trial / NCT02182037

Safety, Pharmacodynamics, and Pharmacokinetics of BIBT 1011 BS in Healthy Subjects

NCT02182037 ↗

Phase 1 Completed 56 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

A study to assess safety, pharmacokinetics and the effect of BIBT 986 BS, given as BIBT 1011 BS, on coagulation parameters.

Timeline

Start
2001-08
Primary completion
2001-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BIBT 1011 BS Unknown 1 mg Oral
Subject BIBT 1011 BS Unknown 5 mg Oral
Subject BIBT 1011 BS Unknown 10 mg Oral
Subject BIBT 1011 BS Unknown 30 mg Oral
Subject BIBT 1011 BS Unknown 100 mg Oral
Subject BIBT 1011 BS Unknown 200 mg Oral
Subject BIBT 1011 BS Unknown 400 mg Oral

Indications

No indication recorded.